Amiloride derivatives are potent blockers of KATP channels.
In cardiomyocytes sarcolemmal KATP channels open massively when the cytosolic [ATP] drops into the range of tens of micromolar, as during acute ischemia. The diuretic drug amiloride and related derivatives are well established as drugs blocking the Na+/H+- and the Na+/Ca2+-exchange, protecting the ischemic heart. Herein, the blocking action of amiloride and its derivatives 2',4'-dichlorobenzamil (DCB) and 5-(N-ethyl-N-isopropyl)amiloride (EIPA) on KATP channels was tested. In inside-out patches of mouse cardiac myocytes, amiloride, DCB, and EIPA reversibly blocked the KATP channels with the IC50 values 102, 1.80, and 2.14 micromol/l (-80 mV), respectively. Similar IC50 values were obtained in recombinant channels when coexpressing the KIR6.2 subunit with one of the sulfonylurea receptors SUR1 and SUR2A. All three drugs also blocked currents generated by the C-terminus deletion mutant KIR6.2delta26 in the absence of SUR. Amiloride blocked outward currents more effectively than inward currents whereas the block by DCB and EIPA was voltage independent. In cardiomyocytes, also whole-cell IKATP was blocked by the three drugs. In conclusion, amiloride, EIPA, and DCB block the pore-forming KIR6.2 subunit of cardiac KATP channels with higher potency than the Na+/H+- and the Na+/Ca2+-exchange, precluding a specific block of the exchanges under ischemic conditions.
Bollensdorff
C
C
Institut für Physiologie, Abteilung Herz-Kreislauf-Physiologie, Friedrich-Schiller-Universität Jena, Germany.
Zimmer
T
T
Benndorf
K
K
D018528:ATP-Binding Cassette Transporters; D000584:Amiloride / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone / Q000494:pharmacology; D004594:Electrophysiology; D006321:Heart / Q000187:drug effects; D054086:KATP Channels; D008564:Membrane Potentials / Q000187:drug effects; D051379:Mice; D009206:Myocardium / Q000166:cytology / Q000378:metabolism; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D010957:Plasmids / Q000235:genetics; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying / Q000187:drug effects / Q000378:metabolism; D018075:RNA, Complementary / Q000096:biosynthesis; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D014475:Uncoupling Agents / Q000494:pharmacology; D014981:Xenopus
D018528:ATP-Binding Cassette Transporters; D054086:KATP Channels; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D018075:RNA, Complementary; D017923:Sodium-Hydrogen Exchangers; D014475:Uncoupling Agents; C092520:uK-ATP-1 potassium channel; C041470:3',4'-dichlorobenzamil; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; D000584:Amiloride; C039614:ethylisopropylamiloride